Interrater Agreement of BT-RADS for Evaluation of Follow-up MRI in Patients with Treated Primary Brain Tumor.

Michael Essien, Maxwell E Cooper, Ashwani Gore, Taejin L Min, Benjamin B Risk, Gelareh Sadigh, Ranliang Hu, Michael J Hoch, Brent D Weinberg
{"title":"Interrater Agreement of BT-RADS for Evaluation of Follow-up MRI in Patients with Treated Primary Brain Tumor.","authors":"Michael Essien, Maxwell E Cooper, Ashwani Gore, Taejin L Min, Benjamin B Risk, Gelareh Sadigh, Ranliang Hu, Michael J Hoch, Brent D Weinberg","doi":"10.3174/ajnr.A8322","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>The Brain Tumor Reporting and Data System (BT-RADS) is a structured radiology reporting algorithm that was introduced to provide uniformity in posttreatment primary brain tumor follow-up and reporting, but its interrater reliability (IRR) assessment has not been widely studied. Our goal is to evaluate the IRR among neuroradiologists and radiology residents in the use of BT-RADS.</p><p><strong>Materials and methods: </strong>This retrospective study reviewed 103 consecutive MR studies in 98 adult patients previously diagnosed with and treated for primary brain tumor (January 2019 to February 2019). Six readers with varied experience (4 neuroradiologists and 2 radiology residents) independently evaluated each case and assigned a BT-RADS score. Readers were blinded to the original score reports and the reports from other readers. Cases in which at least 1 neuroradiologist scored differently were subjected to consensus scoring. After the study, a post hoc reference score was also assigned by 2 readers by using future imaging and clinical information previously unavailable to readers. The interrater reliabilities were assessed by using the Gwet AC2 index with ordinal weights and percent agreement.</p><p><strong>Results: </strong>Of the 98 patients evaluated (median age, 53 years; interquartile range, 41-66 years), 53% were men. The most common tumor type was astrocytoma (77%) of which 56% were grade 4 glioblastoma. Gwet index for interrater reliability among all 6 readers was 0.83 (95% CI: 0.78-0.87). The Gwet index for the neuroradiologists' group (0.84 [95% CI: 0.79-0.89]) was not statistically different from that for the residents' group (0.79 [95% CI: 0.72-0.86]) (χ<sup>2</sup> = 0.85; <i>P</i> = .36). All 4 neuroradiologists agreed on the same BT-RADS score in 57 of the 103 studies, 3 neuroradiologists agreed in 21 of the 103 studies, and 2 neuroradiologists agreed in 21 of the 103 studies. Percent agreement between neuroradiologist blinded scores and post hoc reference scores ranged from 41%-52%.</p><p><strong>Conclusions: </strong>A very good interrater agreement was found when tumor reports were interpreted by independent blinded readers by using BT-RADS criteria. Further study is needed to determine if this high overall agreement can translate into greater consistency in clinical care.</p>","PeriodicalId":93863,"journal":{"name":"AJNR. American journal of neuroradiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392352/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJNR. American journal of neuroradiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3174/ajnr.A8322","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: The Brain Tumor Reporting and Data System (BT-RADS) is a structured radiology reporting algorithm that was introduced to provide uniformity in posttreatment primary brain tumor follow-up and reporting, but its interrater reliability (IRR) assessment has not been widely studied. Our goal is to evaluate the IRR among neuroradiologists and radiology residents in the use of BT-RADS.

Materials and methods: This retrospective study reviewed 103 consecutive MR studies in 98 adult patients previously diagnosed with and treated for primary brain tumor (January 2019 to February 2019). Six readers with varied experience (4 neuroradiologists and 2 radiology residents) independently evaluated each case and assigned a BT-RADS score. Readers were blinded to the original score reports and the reports from other readers. Cases in which at least 1 neuroradiologist scored differently were subjected to consensus scoring. After the study, a post hoc reference score was also assigned by 2 readers by using future imaging and clinical information previously unavailable to readers. The interrater reliabilities were assessed by using the Gwet AC2 index with ordinal weights and percent agreement.

Results: Of the 98 patients evaluated (median age, 53 years; interquartile range, 41-66 years), 53% were men. The most common tumor type was astrocytoma (77%) of which 56% were grade 4 glioblastoma. Gwet index for interrater reliability among all 6 readers was 0.83 (95% CI: 0.78-0.87). The Gwet index for the neuroradiologists' group (0.84 [95% CI: 0.79-0.89]) was not statistically different from that for the residents' group (0.79 [95% CI: 0.72-0.86]) (χ2 = 0.85; P = .36). All 4 neuroradiologists agreed on the same BT-RADS score in 57 of the 103 studies, 3 neuroradiologists agreed in 21 of the 103 studies, and 2 neuroradiologists agreed in 21 of the 103 studies. Percent agreement between neuroradiologist blinded scores and post hoc reference scores ranged from 41%-52%.

Conclusions: A very good interrater agreement was found when tumor reports were interpreted by independent blinded readers by using BT-RADS criteria. Further study is needed to determine if this high overall agreement can translate into greater consistency in clinical care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于评估原发性脑肿瘤患者随访 MRI 的 BT-RADS 的互译一致性。
背景和目的:脑肿瘤报告和数据系统(BT-RADS)是一种结构化的放射学报告算法,其引入的目的是为原发性脑肿瘤治疗后的随访和报告提供统一性,但其交互可靠性(IRR)评估尚未得到广泛研究。我们的目标是评估神经放射科医生和放射科住院医生在使用 BT-RADS 时的内部信度:这项回顾性研究回顾了先前诊断为原发性脑肿瘤并接受治疗的 98 名成人患者的 103 项连续 MR 研究(2019 年 1 月至 2019 年 2 月)。六位具有不同经验的读者(4 位神经放射学专家和 2 位放射学住院医师)独立评估了每个病例,并给出了 BT-RADS 评分。阅读者对原始评分报告和其他阅读者的报告均为盲法。如果至少有一名神经放射学专家对病例的评分不一致,则进行共识评分。研究结束后,2 名读者还使用他们以前无法获得的未来成像和临床信息进行了事后参考评分。使用 Gwet 的 AC2 指数、序数权重和一致性百分比评估了阅读者之间的可靠性:在接受评估的 98 名患者中(中位年龄为 53 岁;四分位数区间为 41-66 岁),53% 为男性。最常见的肿瘤类型是星形细胞瘤(77%),其中56%为4级胶质母细胞瘤。所有六位读片者的互测可靠性的 Gwet 指数为 0.83(95% CI:0.78,0.87)。神经放射科医生组的 Gwet's 指数(0.84 [95% CI: 0.79, 0.89])与住院医生组的 Gwet's 指数(0.79 [95% CI: 0.72, 0.86])无统计学差异(χ2 = 0.85; p = 0.36)。在103项研究中,有57项研究的所有四位神经放射科医师的BT-RADS评分一致,有21项研究的三位神经放射科医师的BT-RADS评分一致,有21项研究的两位神经放射科医师的BT-RADS评分一致。神经放射学家盲法评分与事后参考评分之间的一致率为41%-52%:结论:当独立的盲人读者使用 BT-RADS 标准解释肿瘤报告时,发现了很好的译者间一致性。需要进一步研究以确定这种高度的总体一致性是否能转化为临床护理中更大的一致性:缩写:BI-RADS = 乳房成像报告和数据系统;BT-RADS = 脑肿瘤报告和数据系统;IQR = 四分位数范围;IRR = 交互可靠性;NI-RADS = 颈部成像报告和数据系统。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Association of Pretreatment Perfusion Imaging Parameters With 90-Day Excellent Functional Outcomes in Anterior Circulation Distal Medium Vessel Occlusion Stroke. Deep learning-based algorithm for automatic quantification of nigrosome-1 and Parkinsonism classification using susceptibility map-weighted MRI. High wall shear stress is related to complicated AHA lesion type VI plaques in mild to moderate internal carotid artery stenosis - a 3D cardiovascular MRI study. Prevalence of Spinal Meningeal Diverticula in Autosomal Dominant Polycystic Kidney Disease. Comprehensive Review of Inner Ear Anatomy on Photon-Counting CT.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1